CN102858779B - 环状四肽及其治疗性应用 - Google Patents
环状四肽及其治疗性应用 Download PDFInfo
- Publication number
- CN102858779B CN102858779B CN201180019907.7A CN201180019907A CN102858779B CN 102858779 B CN102858779 B CN 102858779B CN 201180019907 A CN201180019907 A CN 201180019907A CN 102858779 B CN102858779 B CN 102858779B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- acceptable salt
- taken together
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*C(C(NC)=O)N(*=C)C(C(*)N(*)C(C)=O)=O Chemical compound C*C(C(NC)=O)N(*=C)C(C(*)N(*)C(C)=O)=O 0.000 description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- VFSFCYAQBIPUSL-UHFFFAOYSA-N C(C1)C1c1ccccc1 Chemical compound C(C1)C1c1ccccc1 VFSFCYAQBIPUSL-UHFFFAOYSA-N 0.000 description 2
- ZRNUSQJWDQEUID-QORCZRPOSA-N N[C@H](CC(N(CCC1)[C@@H]1C(N(CCC1)[C@@H]1C(N[C@@H](Cc1ccccc1)C(O)=O)=O)=O)=N)Cc1ccccc1 Chemical compound N[C@H](CC(N(CCC1)[C@@H]1C(N(CCC1)[C@@H]1C(N[C@@H](Cc1ccccc1)C(O)=O)=O)=O)=N)Cc1ccccc1 ZRNUSQJWDQEUID-QORCZRPOSA-N 0.000 description 1
- IDCGAISDYMKEMG-GENLYUKMSA-N O[C@@H](C1)C(C2)C2(C(NC(C2)(CC(N[C@@H](Cc3ccccc3)C(N3C4(C5)C5CC3)=O)=O)C2C2C=CC=CC2)O)N1C4=O Chemical compound O[C@@H](C1)C(C2)C2(C(NC(C2)(CC(N[C@@H](Cc3ccccc3)C(N3C4(C5)C5CC3)=O)=O)C2C2C=CC=CC2)O)N1C4=O IDCGAISDYMKEMG-GENLYUKMSA-N 0.000 description 1
- WBPASDYDIYMTLJ-DNZIZEQUSA-N Oc1ccc(C[C@@H](C(N(CCC2)[C@@H]2C(N2[C@H]3CCC2)=O)=O)NCC[C@H](Cc2ccccc2)NC3=O)cc1 Chemical compound Oc1ccc(C[C@@H](C(N(CCC2)[C@@H]2C(N2[C@H]3CCC2)=O)=O)NCC[C@H](Cc2ccccc2)NC3=O)cc1 WBPASDYDIYMTLJ-DNZIZEQUSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
- C07K5/126—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PLP.390493 | 2010-02-19 | ||
| PL390493A PL219569B1 (pl) | 2010-02-19 | 2010-02-19 | Cykliczne tetrapeptydy i ich zastosowanie |
| PCT/US2011/025571 WO2011103524A2 (en) | 2010-02-19 | 2011-02-19 | Cyclic tetrapeptides and therapeutic applications thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102858779A CN102858779A (zh) | 2013-01-02 |
| CN102858779B true CN102858779B (zh) | 2016-08-03 |
Family
ID=44483608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180019907.7A Expired - Fee Related CN102858779B (zh) | 2010-02-19 | 2011-02-19 | 环状四肽及其治疗性应用 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20130224232A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2536732B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5901543B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101704665B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102858779B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011217882B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112012020833A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2827694C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2611663T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL221535A (cg-RX-API-DMAC7.html) |
| PL (1) | PL219569B1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2568436C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011103524A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL219569B1 (pl) | 2010-02-19 | 2015-05-29 | Peptaderm Spółka Z Ograniczoną Odpowiedzialnością | Cykliczne tetrapeptydy i ich zastosowanie |
| WO2016179398A1 (en) | 2015-05-05 | 2016-11-10 | Washington University | Isoform-selective lysine deacetylase inhibitors |
| US10154997B2 (en) | 2015-08-04 | 2018-12-18 | Washington University | Treatment of parasitic diseases using KDAC inhibitor compounds |
| US11325944B2 (en) | 2017-06-16 | 2022-05-10 | University Of Florida Research Foundation, Incorporated | Macrocyclic peptides and derivatives thereof with opioid activity |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3862925A (en) * | 1973-07-05 | 1975-01-28 | American Home Prod | Preparation of somatotropin release inhibiting factor and intermediates therefor |
| US3842067A (en) | 1973-07-27 | 1974-10-15 | American Home Prod | Synthesis of(des-asn5)-srif and intermediates |
| JPS5726506B2 (cg-RX-API-DMAC7.html) * | 1974-03-08 | 1982-06-04 | ||
| IT1077010B (it) * | 1976-09-01 | 1985-04-27 | Snam Progetti | Processo per la preparazione di copolimeri dell isobutilene contenenti insaturazioni ed atomi di alogeno reattivi |
| US4105603A (en) | 1977-03-28 | 1978-08-08 | The Salk Institute For Biological Studies | Peptides which effect release of hormones |
| JPH0334991A (ja) * | 1989-06-30 | 1991-02-14 | Shionogi & Co Ltd | 環状テトラペプチドおよびその製造法 |
| US5216124A (en) | 1989-12-15 | 1993-06-01 | G. D. Searle & Co. | Substituted cyclic tetrapeptides |
| US5541287A (en) | 1992-06-09 | 1996-07-30 | Neorx Corporation | Pretargeting methods and compounds |
| US6777217B1 (en) * | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
| US6013763A (en) * | 1996-06-04 | 2000-01-11 | Genentech, Inc. | Peptide variants of protein A |
| US6281331B1 (en) | 1998-03-23 | 2001-08-28 | Trimeris, Inc. | Methods and compositions for peptide synthesis |
| EP1071442B9 (en) * | 1998-03-23 | 2006-01-18 | Trimeris Inc. | Methods and compositions for peptide synthesis (t-20) |
| DE19816922A1 (de) | 1998-04-16 | 1999-10-21 | Wolfgang Beck | Einfache Synthese von cyclischen Tetrapeptiden aus nichtaktivierten Peptidestern an Metallzentren |
| AUPP505798A0 (en) * | 1998-08-04 | 1998-08-27 | Fujisawa Pharmaceutical Co., Ltd. | Novel compound fr225497 substance |
| CZ20011342A3 (cs) | 1998-10-13 | 2001-09-12 | Fujisawa Pharmaceutical Co., Ltd. | Cyklické tetrapeptidy |
| GB9903087D0 (en) * | 1999-02-12 | 1999-03-31 | Glaxo Group Ltd | Process |
| DE602004009710T2 (de) * | 2003-12-31 | 2008-08-07 | F. Hoffmann-La Roche Ag | Verfahren zur peptidsynthese unter verwendung einer reduzierten menge an entschützungsmittel |
| WO2006049597A1 (en) | 2004-10-27 | 2006-05-11 | Avanir Pharmaceuticals | Amino acid-derived compounds as modulators of the reverse cholesterol transport |
| CN101115495B (zh) * | 2004-12-14 | 2011-06-22 | 生物如恩克斯株式会社 | 通过runx2乙酰化作用增强bmp的骨形成活性的方法 |
| EP2061512B1 (en) | 2006-08-23 | 2019-10-02 | Yeda Research And Development Co. Ltd. | Conjugates of rgd peptides and (bacterio)chlorophyll photosensitizers and their uses |
| CN102036684B (zh) | 2008-02-27 | 2017-06-09 | 耶达研究及发展有限公司 | 用于光动力疗法和坏死肿瘤成像的rgd‑(细菌)叶绿素缀合物 |
| WO2010006267A2 (en) * | 2008-07-11 | 2010-01-14 | University Of Kansas | Cyclic tetrapeptides |
| GB0918579D0 (en) | 2009-10-22 | 2009-12-09 | Imp Innovations Ltd | Gadd45beta targeting agents |
| PL219569B1 (pl) | 2010-02-19 | 2015-05-29 | Peptaderm Spółka Z Ograniczoną Odpowiedzialnością | Cykliczne tetrapeptydy i ich zastosowanie |
-
2010
- 2010-02-19 PL PL390493A patent/PL219569B1/pl unknown
-
2011
- 2011-02-19 KR KR1020127024471A patent/KR101704665B1/ko not_active Expired - Fee Related
- 2011-02-19 ES ES11745399.3T patent/ES2611663T3/es active Active
- 2011-02-19 AU AU2011217882A patent/AU2011217882B2/en not_active Ceased
- 2011-02-19 CA CA2827694A patent/CA2827694C/en not_active Expired - Fee Related
- 2011-02-19 CN CN201180019907.7A patent/CN102858779B/zh not_active Expired - Fee Related
- 2011-02-19 EP EP11745399.3A patent/EP2536732B1/en not_active Not-in-force
- 2011-02-19 JP JP2012554079A patent/JP5901543B2/ja not_active Expired - Fee Related
- 2011-02-19 WO PCT/US2011/025571 patent/WO2011103524A2/en not_active Ceased
- 2011-02-19 US US13/579,933 patent/US20130224232A1/en not_active Abandoned
- 2011-02-19 RU RU2012139668/04A patent/RU2568436C2/ru not_active IP Right Cessation
- 2011-02-19 BR BR112012020833A patent/BR112012020833A2/pt not_active Application Discontinuation
-
2012
- 2012-08-19 IL IL221535A patent/IL221535A/en not_active IP Right Cessation
- 2012-08-24 US US13/593,716 patent/US9382292B2/en not_active Expired - Fee Related
-
2013
- 2013-01-27 IL IL224410A patent/IL224410A/en not_active IP Right Cessation
-
2016
- 2016-07-04 US US15/201,565 patent/US10238713B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL224410A (en) | 2017-07-31 |
| KR20130088004A (ko) | 2013-08-07 |
| EP2536732B1 (en) | 2016-10-19 |
| CA2827694A1 (en) | 2011-08-25 |
| WO2011103524A2 (en) | 2011-08-25 |
| AU2011217882A1 (en) | 2012-10-11 |
| JP5901543B2 (ja) | 2016-04-13 |
| US20130108655A1 (en) | 2013-05-02 |
| BR112012020833A2 (pt) | 2017-12-19 |
| IL221535A (en) | 2016-08-31 |
| US20170157204A1 (en) | 2017-06-08 |
| US20130224232A1 (en) | 2013-08-29 |
| JP2013520440A (ja) | 2013-06-06 |
| RU2568436C2 (ru) | 2015-11-20 |
| PL390493A1 (pl) | 2011-08-29 |
| AU2011217882B2 (en) | 2015-02-05 |
| US9382292B2 (en) | 2016-07-05 |
| US10238713B2 (en) | 2019-03-26 |
| WO2011103524A3 (en) | 2011-12-29 |
| PL219569B1 (pl) | 2015-05-29 |
| KR101704665B1 (ko) | 2017-02-08 |
| CA2827694C (en) | 2018-09-18 |
| EP2536732A4 (en) | 2014-04-30 |
| ES2611663T3 (es) | 2017-05-09 |
| RU2012139668A (ru) | 2014-03-27 |
| WO2011103524A8 (en) | 2012-09-13 |
| EP2536732A2 (en) | 2012-12-26 |
| CN102858779A (zh) | 2013-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6007187B2 (ja) | デガレリクスおよびその中間体を製造する方法 | |
| US9260480B2 (en) | Process for the manufacture of Degarelix and its intermediates | |
| KR100437985B1 (ko) | 신규한 돌라스타틴 유도체, 그들의 제법 및 용도 | |
| CN102858779B (zh) | 环状四肽及其治疗性应用 | |
| NZ299913A (en) | Treatment of cancer using polypeptide bombesin/GRP antagonists | |
| JP3568952B2 (ja) | ５位及び６位に修飾アミノアシル残基を有するｌｈｒｈ拮抗薬 | |
| US5731285A (en) | Tachiquinine antagonist tricyclic compounds, preparation of same and pharmaceutical compositions containing such compounds | |
| Bańkowski et al. | Synthesis, biological activity and resistance to proteolytic digestion of new cyclic dermorphin/deltorphin analogues | |
| AU671118B2 (en) | Tachykinin antagonist tricyclic compounds, preparation of same and pharmaceutical compositions containing such compounds | |
| EP0452447A1 (en) | Reduced irreversible bombesin antagonists | |
| US5786447A (en) | Opioid peptide analogs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160803 Termination date: 20210219 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |